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Abstract
Adjunctive vitamin D treatment for pulmonary tuberculosis enhances resolution of inflam-
mation but has modest effects on bacterial clearance. Sodium 4-phenylbutyrate (PBA) is in
clinical use for a range of conditions and has been shown to synergise with vitamin D
metabolites to upregulate cathelicidin antimicrobial peptide (CAMP) expression. We investi-
gated whether clinically attainable plasma concentrations of PBA (0.4-4mM) directly affect
Mycobacterium tuberculosis (Mtb) growth and human macrophage and PBMC response to
infection. We also tested the ability of PBA to enhance the immunomodulatory actions of
the vitamin D metabolite 25(OH)D3 during infection and synergistically inhibit intracellular
Mtb growth. PBA inhibitedMtb growth in broth with an MIC99 of 1mM, which was reduced to
0.25mM by lowering pH. During human macrophage infection, PBA treatment restricted
Mtb uptake, phagocytic receptor expression and intracellular growth in a dose-dependent
manner. PBA independently regulated CCL chemokine secretion and induced expression
of the antimicrobial LTF (lactoferrin), the anti-inflammatory PROC (protein C) and multiple
genes within the NLRP3 inflammasome pathway. PBA co-treatment with 25(OH)D3 syner-
gistically modulated expression of numerous vitamin D-response genes, including CAMP,
CYP24A1, CXCL10 and IL-37. This synergistic effect was dependent on MAPK signalling,
while the effect of PBA on LTF, PROC and NLRP3 was MAPK-independent. During PBA
and 25(OH)D3 co-treatment of human macrophages, in the absence of exogenous protein-
ase 3 (PR3) to activate cathelicidin,Mtb growth restriction was dominated by the effect of
PBA, while the addition of PR3 enhanced growth restriction by 25(OH)D3 and PBA co-treat-
ment. This suggests that PBA augments vitamin D–mediated cathelicidin-dependentMtb
growth restriction by human macrophages and independently induces antimicrobial and
anti-inflammatory action. Therefore through both host-directed and bacterial-directed
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mechanisms PBA and vitamin D may prove an effective combinatorial adjunct therapy for
tuberculosis to both resolve immunopathology and enhance bacterial clearance.
Author Summary
Tuberculosis (TB) is the world’s leading bacterial cause of death. Effective treatment cur-
rently requires a minimum of 4 drugs taken for at least 6 months. While these drugs kill
the TB causing bacteria (Mtb), they do not directly resolve the inmmunopathology associ-
ated with morbidity. Immunomodulatory agents that not only enhance an individual’s
ability to killMtb but also help heal lung pathology could be used as adjuncts to current
therapies to improve treatment outcome. Phenylbutyrate (PBA) has been in clinical use
for more than 30 years to treat a range of conditions. It has also been shown to synergise
with vitamin D to induce cellular production of the anti-Mtb peptide, cathelicidin. We
investigated whether PBA and vitamin D synergistically killMtb in human macrophages
and whether PBA has any independent effect on macrophages andMtb. At concentrations
that are achieved in plasma clinically, PBA inhibitedMtb growth. PBA also inhibited
growth ofMtb in human macrophages via a cell-dependent mechanism, inducing the
inflammasome pathway and antimicrobial lactoferrin. PBA also synergistically enhanced
macrophage response to vitamin D and co-treatment further inhibitedMtb growth, when
synergistically-induced cathelicidin was activated. PBA and vitamin D may therefore
prove an effective combinatorial adjunct therapy for tuberculosis.
Introduction
Tuberculosis (TB) is the world’s leading bacterial cause of death, with 9 million new cases and
1.5 million deaths in 2013 [1]. Despite the availability of antimicrobials, effective treatment
regimes require long-term administration of multiple drugs, which can lead to toxicity, prob-
lems with adherence and the development of drug resistance. Current drug regimes, while
reducing bacterial load, do not directly resolve the immunopathological inflammatory
responses associated with morbidity [2, 3]. Immunomodulatory agents that augment antimi-
crobial activity and accelerate resolution of pulmonary inflammation could be used as adjuncts
to antimicrobial therapy to improve treatment outcomes [4].
The active metabolite of vitamin D3, 1α25-dihydroxy-vitamin D3 [1α,25(OH)2D3] inhibits
intracellular growth ofMycobacterium tuberculosis (Mtb) in peripheral blood mononuclear
cells (PBMC) and monocytes (MN) and suppresses pro-inflammatory cytokine secretion in
vitro [5, 6]. LL-37 (cathelicidin) has been identified as a mediator of vitamin D-dependent anti-
microbial activity [7]. Pro-LL-37 (hCAP-18) is transcribed from the cathelicidin antimicrobial
peptide (CAMP;OMIM 600474) gene that contains 3 vitamin D response elements (VDRE) in
its promoter and requires enzymatic digestion by human neutrophil proteinase 3 (PR3; OMIM
177020) to produce mature LL-37 (OMIM 600474), an antimicrobial that directly inhibitsMtb
growth [5, 8]. The presence of VDRE in the CAMP promoter is an evolutionary adaptation,
having only been identified in chimpanzee and human DNA sequences [9]; as such the antimi-
crobial action of vitamin D mediated by CAMP is limited to higher-order primates. LL-37 also
regulates autophagy-mediated killing via induction of autophagy related proteins Beclin-1
(OMIM 604378) and Atg5 (OMIM 604261) [10] and has chemotactic activity for polymorpho-
nuclear leukocytes [11].
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1α,25(OH)2D3 is synthesised from the major circulating form of vitamin D3, 25-hydroxy-
vitamin D3 [25(OH)D3], by the vitamin D 1α-hydroxylase enzyme (CYP27B1; OMIM 609506)
the expression of which is upregulated in leukocytes following ligation of toll-like receptors
withMtb ligands [12]. Vitamin D deficiency (defined as a circulating concentration<50nM 25
(OH)D) is associated with susceptibility to tuberculosis [13, 14]. We have shown that adminis-
tration of adjunctive vitamin D accelerates resolution of inflammatory responses during tuber-
culosis treatment [15], and that this is associated with a trend towards accelerated sputum
culture conversion [16]. The limited in vivo effect of vitamin D supplementation onMtb
growth despite significant inhibition in vitromay be due to the fact that the majority of in vitro
experiments have used supra-physiological doses of 1α,25(OH)2D3 (100nM vs. the circulating
concentration of 100pM). Physiological doses (100nM) of 25(OH)D3 have only shown a signif-
icant effect onMtb growth in vitro during co-stimulation with other molecules, such as IFNγ
(OMIM 147570) or IL-15 (OMIM 600554), to prolong transcription of CYP27B1 [6, 17, 18].
Sodium 4-phenylbutyrate (PBA) is an aromatic short chain fatty acid which has been in
clinical use for more that 30 years. As a pro-drug for sodium phenylacetate it is used to control
nitrogen disposal in urea disorders, as a chemical chaperone it is used to alleviate endoplasmic
reticulum stress in type-2 diabetes, and as a histone deacetylase inhibitor (HDACi) it is used to
treat various leukaemias and cancers via modulating chromatin structure and inducing cellular
differentiation and apoptosis [19–24]. PBA has also been shown to have direct anti-fungal
activity against Candida albicans and Cryptococcus neoformans [25]. Moreover, PBA synergises
with the 1α,25(OH)2D3 induction of CAMP expression, in a variety of cell lines [26, 27]. This
synergistic induction of CAMP expression was also recently confirmed ex vivo in PBMC from
healthy control participants in a dose-finding study who received oral PBA and vitamin D3 for
8 days [28], also confirming the systemic effect of this treatment on immune cell function. On
the basis of this synergistic CAMP induction, there is an on-going phase 2 trial of PBA and vita-
min D3 adjunct therapy for TB [29]. However, the direct effect of PBA onMtb and human
immune cells is unknown. Data are also lacking on the question of whether this combined co-
treatment has additional synergistic effects on macrophage function duringMtb-infection and
if it can synergistically inhibit intracellularMtb growth via CAMP induction. Thus, we investi-
gated each of these questions, determining the effects of clinically attainable plasma concentra-
tions of PBA (0.4-4mM), alone and in combination with the physiologically relevant vitamin D
metabolite 25(OH)D3, at optimal concentration for immune function.
Results
PBA directly restrictsMtb growth
To test whether PBA has direct anti-mycobacterial effects,Mtb was grown on both solid agar
medium and in broth in the presence of a 10-fold serial dilution (0.4-4mM) of PBA. Plating a
low density culture on solid medium containing 4mM PBA completely restricted growth, while
the presence of 0.4mM PBA allowed 70% growth and 0.04mM allowed 84% growth, compared
to vehicle control (0mM, 0.4% water) (Fig 1A). When PBA was added to exponentially growing
rolling broth cultures, 4mM PBA significantly inhibited an increase in OD600 from day 2
onwards (P<0.0001) and this was maintained until day 14 at which stage cultures were pel-
leted, washed and resuspended in PBA-free medium (Fig 1B). Growth inhibition by 4mM PBA
was maintained in PBA-free medium for a further 8 days and growth never reached control
levels (P<0.0001) (Fig 1B). Reductions in OD600 were confirmed by colony forming unit
(CFU) analysis, with 4mM PBA reducing CFU to 6% of control after 6 days of treatment (Fig
1C). The retardation of growth following removal of 4mM PBA from the medium suggests
that PBA is bacteriostatic rather than bactericidal and it may modify bacterial replication.
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Phenotypically when exponential phase cultures were grown in the presence of 4mM PBA,
even in the presence of a detergent, the cultures formed a cord like conglomerate that was easily
dispersed by swirling. This suggested that there may be a cell wall modification by PBA, result-
ing in the bacteria having an adherent phenotype. Confocal microscopy of GFP-expressing
H37Rv confirmed that PBA-treated bacilli are often found bound along the entire shaft of
neighbouring bacilli, forming lined-up clusters (S1A Fig), unlike untreated cultures which had
single bacilli or overlapping bacilli when in clusters (S1B Fig). Non GFP-expressing bacteria
were also found within these PBA clusters of lined-up bacilli indicating that they were not met-
abolically active (S1A Fig).
As a weak acid, PBA activity may be modulated by the pH of the growth medium. We con-
firmed that there was no significant effect of PBA on pH of growth medium from infected and
uninfected cultures (S2 Fig). We then tested a 2-fold serial pH reduction over a range of PBA
concentrations (0.25–4mM) using the Alamar Blue reduction checkerboard assay. The mini-
mum inhibitory concentration of PBA which stopped 99% ofMtb growth (MIC99) without
HCl was 1mM and this was reduced to 0.5mM in the presence of 2.5mMHCl and to 0.25mM
in the presence of 5mMHCl, with 10mMHCl completely inhibitingMtb growth irrespective
of PBA (Fig 1D). At these HCl concentrations growth medium pH reduced from 6.61 to 6.37,
6.06 and 4.82, respectively (Fig 1D).Mtb containing phagosomes have a pH range of 6.5 to 6.2
and become acidified to pH 5.8 to 5.6 when infected with attenuatedMtb, and can reach a pH
of 5.0 to 4.5 upon phagolysosome fusion [30, 31]. Thus, PBA may have enhanced activity
againstMtb as phagosomes become increasingly acidified.
Fig 1. PBA inhihibtsMtb H37Rv growth on solid and in liquid medium. (A)Mtb 21 day growth on solid medium a 10-fold serial dilutin of PBA. (B) Growth
ofMtb in rolling broth culutre as monitored by OD600 after addition of PBA on day 4 to a final concentration of 0.4-4mM PBA. 10-day treated culutres were
washed and resuspended in PBA-free medium with growth monitored for a further 8 days. (C)Mtb growth in broth (B), assessed by CFU. (D) Checkerboard
Alamar Blue reduction assay measuring MIC99 of PBA in the presence of 2-fold serial dilution of HCl, with pH of medium indicated. Growth occurs in pink
wells with visible whiteMtb pellets. Mean ± SEM, for dupicate experimetns, CFU plated in triplicate from growth curves, growth curves and Alamar Blue
respresentative of replicate experiments, anlaysed by 1-way ANOVA, with Bonferroni multiple comparison test (A,C), or 2-way ANOVA, with Dunnett's
multiple comparison test (B); *, P<0.05; **, P<0.01; ***, P<0.001, ****, P<0.0001.
doi:10.1371/journal.ppat.1005007.g001
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PBA restrictsMtb uptake and intracellular growth by PBMC and
macrophages
Once we had determined PBA had a direct effect onMtb, we next investigated the effect of
PBA on the human cellular response toMtb. Initially, a 2-fold serial dilution of PBA (0.5-
8mM) was added to PBMC at the time ofMtb infection. Uptake was significantly inhibited 4
hrs post-infection by 8mM PBA (to 54% of control, P = 0.0009) and intracellular growth was
inhibited after 96 hrs in PBMC, in a dose-dependent manner: there with a trend for decreased
growth with 4mM PBA (71% of control) and a significant inhibition of growth with 8mM PBA
(45% of control, P = 0.01) (Fig 2A).
The inhibition ofMtb uptake when PBA was added at the time of infection suggests PBA
may directly affect phagocytic function. To confirm this, monocyte-derived macrophages
(MDM) were pre-treated for 48 hrs with PBA, washed and then infected withMtb in PBA-free
medium. Pre-treatment significantly inhibited MDM uptake ofMtb to 64% of control (P = 0.02,
Fig 2B). To determine if this was associated with inhibited expression of phagocytic receptors,
macrophages were analysed for surface expression of CD35 (CR1, OMIM 120620), CD11b
Fig 2. PBA restictsMtb uptake and intracellular growth in PBMC and MDM. (A) Uptake ofMtbH37Rv by PBMC 4 hrs post-infection and intracellular
growth 96 hr-post-infection in the presence of a 2-fold serial dilution of PBA. (B)Mtb uptake by MDM pre-treated with 4mMPBA for 48 hrs. (C) Phagocytic receptor
expression (CD11b, CD11c, CD16 or CD35) on MDM following 48 hrs 4mMPBA treatment:percent of live cells expressing receptors andmedian fluorescent
index (MFI), by flow cytometry. (D) IntracellularMtb growth inMDM treated with a serial dilution of PBA 4 hrs post-infection, measured by CFU. (E) Seven day
intracellular growth of 4mMPBA pre-treatedMtb, and controlMtb, grown in MDM ± 4mMPBA post-infection. Mean ±SD or min-max (box plots), n = 3–4 in
triplicate for CFU and n = 8 for flow cytometry; 1-way ANOVAwith Dunnett’s multiple comparisons test (A,E,F) or Paired t-test (B,C,D): *, P<0.05, ***, P<0.001.
doi:10.1371/journal.ppat.1005007.g002
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(CR3, OMIM 120980), CD11c (CR4, OMIM 151510), and CD16 (FcγR, OMIM 146740) by flow
cytometry. PBA pre-treatment did not affect the number of MDM expressing each receptor but
it did significantly inhibit median fluorescent index of CD11b and CD11c (Fig 2C).
The effect of PBA onMtb intracellular growth in MDM was subsequently assessed by treat-
ing MDM with PBA 4 hrs post-infection, to ensure comparable infection of cells pre-treatment.
There was a trend for decreased intracellular growth with 4mM PBA (74%) after 72 hrs of
infection, while 2-4mM PBA restricted growth after 7 days (to 55% and 37% of control, respec-
tively, P<0.012, Fig 2D). To elucidate whetherMtb growth inhibition was mediated via a cellu-
lar-dependent mechanism or if it was due to the direct effect of PBA onMtb growth,Mtb was
cultured for 4 days in the presence/absence of 4mM PBA, extensively washed to remove PBA
and then MDM were infected for 4 hrs and cultured in medium without PBA for 7 days. CFU
analysis indicated that there was no significant effect of PBA pre-treatment ofMtb on infection
dose or 4 hrs uptake (S3 Fig) and only a small non-significant reduction inMtb growth after 7
days (Fig 2E). Conversely when MDM from the same donors were infected with untreatedMtb
and MDM were treated post-infection with 4mM PBAMtb growth was significantly inhibited
(P = 0.018, Fig 2E). This suggests that PBA also has a direct effect on cell-mediated growth
restriction and that the ability of PBA to restrict the growth of intra-phagosomal bacteria is
more likely mediated via a host-directed mechanism than via the direct action of PBA.
PBA regulates macrophage transcriptional response toMtb infection
To investigate how PBA regulates macrophage response toMtb infection, MDM gene expres-
sion was analysed using real-time reverse transcription-polymerase chain reaction (RT-PCR)
arrays designed for a panel of 28 immune response and vitamin D-associated genes. Initially,
to gain a broad sense of the transcriptional regulation by PBA, expression results from infected
and uninfected MDM at 24 and 72 hrs post-infection (20 and 68 hrs post-treatment) were
combined for analysis, applying a t-test for general linear models (GLM) with statistical adjust-
ment for donor variation and time of treatment. Principal component analysis (PCA) con-
ducted using the 12 genes identified to be significantly regulated by PBA, irrespective of time
and infection status, showed that PBA had the greatest effect on gene expression in infected
cells (Fig 3A). We then applied a similar GLM analysis to data from only infected cells, and
found PBA had a greater effect on gene expression after 72 hrs (Fig 3B).
Gene expression data were then analysed separating samples from each time point and
infection status, to identify all genes regulated by PBA under the different conditions (Table 1).
PBA only affected uninfected cells after 72 hrs: seven genes were upregulated, six of which were
also upregulated duringMtb infection (CAMP, CXCL8 (OMIM 146930), IL1B (OMIM
147720), IL12A (OMIM 161560), PROC (OMIM 176860), VDR (OMIM 601769)) and one
gene was inhibited (CYP27B1).
DuringMtb infection, 18 genes were regulated by PBA: 10 genes were induced at 24 hrs and
12 genes at 72hrs, with eight genes induced at both time points (CASP1 (OMIM 147678),
CXCL8, IL1B, IL36G (OMIM 605542), IL37(OMIM 605510), LTF (OMIM 150210), PROC,
TREM1 (OMIM 605085)), while four genes were inhibited and only at 24 hrs (ARG1 (OMIM
608313), CXCL7 (OMIM 121010), CYP27B1, IL10 (OMIM 124092)) (Table 1). The effect of
PBA on gene expression was also dose-dependent (S4 Fig). However, while PBA had a greater
effect on the number of genes regulated when treatment occurred during infection, the fold
change in expression regulated by PBA was actually higher in uninfected cells (Table 1), sug-
gesting thatMtb-infection interferes with the effect of PBA treatment.
The 2 genes most highly induced by PBA during infection, were LTF and PROC. LTF
encodes lactoferrin, an iron chelator with known anti-Mtb effects [32], which PBA induced
Phenylbutyrate and Vitamin D: Dual Immunotherapy for Tuberculosis
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approximately 6-fold (P<0.022), the effect of PBA being infection-dependent (Fig 3C). PROC,
which encodes anticoagulant protein C, an anti-inflammatory molecule which supresses cyto-
kine production and secretion [33] had the greatest induction (15–23 fold, P<0.01), irrespec-
tive of infection (Fig 3C and Table 1). CAMP expression was also induced, but only 3-4-fold
(P0.019) 72 hrs post-treatment (Table 1).
Of the 8 genes regulated by PBA duringMtb infection at both time points, four were
involved in the inflammasome and IL-1 pathway; IL1B, IL36G (IL1F9), IL37 (IL1F7b) and
CASP1 (required for IL-1β post-translational activation) were induced. NCF4 (OMIM 601488)
which transcribes a subunit (p40-phox) of NAPDH oxidase which activates the NLRP3 inflam-
masome, and NLRP3 (OMIM 606416) were both induced by PBA during infection, at 24 and
72 hrs, respectively (P0.026). Six additionalMtb-associated genes encoding cytokines and
chemokines were also regulated by PBA. Of these, CXCL8 (IL-8) and IL12A (IL-12p35) had the
greatest induction of expression (3-6-fold, P = 0.009) (Fig 3C and Table 1).
PBA regulates macrophage chemokine secretion duringMtb infection
The effect of PBA on macrophage secretion of a panel of 30 chemokines, cytokines and growth
factors in supernatants 24 and 72 hrs post-infection was then analysed, using a t-test for GLM
Fig 3. PBAmodulates gene transcription bymacrophages, irrespective ofMtb infection. (A) Principal component anlaysis (PCA) of the 12 genes
significantly regulated by PBA, irrespective of time and infection status. Each point represents one donor and condition, and its position in the plot is
determined by the combined effects of all 12 genes for that treatment, time and infection type. The distance between points represents Euclidean distance.
The first 3 component vectors are displayed, along with a % figure signifying the proportion of the variability in the data that each component accounts for.
Points are coloured according to treatment type (left) or infection status (right). (B) PCA analysis ofMtb-infected cells coloured by treatment (left) or time of
sampling (right). (C) Pattern of gene expression of 5 genes regualted by PBA (blue) vs control (black) inMTb-infected (circles, solid-lines) and uninfected
MDM (squares, dashed-lines). (D) Protein secretion by MDM 72hr post-Mtb infection. Mean ± SD, n = 4–5; P-values from t-test for GLM, with adjustment for
donor variation (Table 1); *, P<0.05; **, P<0.01.
doi:10.1371/journal.ppat.1005007.g003
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with adjustment for donor variation. Similar to the effects on transcript abundance, PBA had a
greater effect on protein secretion 72 hrs post-infection, modulating secretion of five analytes,
compared to only one at 24 hrs (Fig 3D and Table 1). A dose-response was also confirmed for
these proteins (S5 Fig). Four of the five analytes were C-C ligand (CCL) chemokines: CCL2
(OMIM 158105) secretion was inhibited by PBA at 24 and 72 hrs (P0.027), while CCL3
(OMIM 182283), CCL4 (OMIM 182284) and CCL5 (OMIM 187011) had increased secretion
after 72 hrs (Fig 3D, P0.036). The concentration of soluble IL-2R (OMIM 146710) was also
significantly higher in PBA treated cultures at 72 hrs (P = 0.0018).
PBA and 25(OH)D3 synergistically and independently modulate MDM
immune response toMtb
Since PBA had a significant effect on macrophage gene expression and protein secretion during
Mtb infection, we next investigated the hypothesis that PBA synergises with 25(OH)D3 regu-
lated gene expression duringMtb infection. Dose response experiments showed 100nM 25
Table 1. Effect of 4mM PBA onMDM gene expression and protein secretion.
Mtb-infected Uninfected
24 hrs 72 hrs 72 hrs1
Analyte Fold change2 P Fold change P Fold change P
mRNA PROC 15.31 0.0015 20.14 0.0096 23.33 0.0017
LTF 6.78 0.0079 6.23 0.0225 - ns
IL36G 5.52 0.0213 6.62 0.0229 - ns
IL1B 4.29 0.0116 3.82 0.0252 6.56 0.0036
IL37 3.80 0.0028 5.26 0.0099 - ns
IL23A 2.84 0.0094 - ns - ns
CXCL8 1.92 0.0461 3.24 0.0090 6.92 0.0045
TREM1 1.85 0.0453 2.82 0.0427 - ns
CASP1 1.81 0.0001 2.12 0.0487 - ns
NCF4 1.53 0.0042 - ns - ns
ARG1 -1.45 0.0085 - ns - ns
CYP27B1 -1.61 0.0347 - ns -6.25 0.0005
IL10 -2.74 0.0208 - ns - ns
CXCL7 -4.03 0.0104 - ns - ns
IL12A - ns 6.21 0.0093 2.35 0.0067
CAMP - ns 3.40 0.0030 3.90 0.0189
NLRP3 - ns 2.44 0.0263 - ns
VDR - ns 2.14 0.0121 2.42 0.0096
IFNB1 - ns - ns 1.72 0.0168
Protein CCL3 - ns 19.73 0.0032
CCL5 - ns 6.91 0.0023
IL-2R - ns 5.99 0.0018
CCL4 - ns 3.16 0.0363
CCL2 -10.54 9.17x10-5 -5.78 0.0269
1Uninfected mRNA had no genes signiﬁcant affected by PBA at 24 hrs (q0.1).
2Fold change and P-value from t-test for GLM with adjustment for subject ID (repeated measures, n = 5), on samples from the speciﬁed time point and
infection status, non-signiﬁcant (ns) if false discovery rate (q-value) >0.1
doi:10.1371/journal.ppat.1005007.t001
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(OH)D3 was the optimal physiological concentration for transcriptional activation (serum
levels 220nM are considered toxic [34]) (S6 Fig). MDMwere therefore treated 4 hrs post-
infection with 4mM PBA, 100nM 25(OH)D3 or in combination and RNA was isolated 24 and
72 hrs post-infection for analysis by RT-PCR arrays, as before. To identify the synergistic effects
of PBA and 25(OH)D3 during co-treatment, a t-test for GLM, with adjustment for donor varia-
tion and time of treatment, was applied to three comparisons: 25(OH)D3 vs. control, co-treat-
ment vs. control, and co-treatment vs. PBA (to determine the effect of 25(OH)D3 in the
presence of PBA), including samples from both time points. A total of 20 genes were identified
to be significantly regulated in at least one of the three treatment conditions (Table 2).
Hierarchical clustering applied to the list of 20 differentially regulated genes showed that 25
(OH)D3- and co-treated samples clustered together, indicating that 25(OH)D3 had the greatest
contribution to differential gene expression during co-treatment. PBA-treated samples formed
their own cluster and all treatments clustered according to time of sampling, with 72 hrs sam-
ples showing a greater effect of each treatment (Fig 4A).
Of the 13 genes regulated by 25(OH)D3, six were also regulated by PBA monotherapy
(although the effect of 25(OH)D3 on their expression was greater: four were induced [CAMP,
Table 2. Effect of 25(OH)D and PBA co-treatment onMtb-infected MDM gene expression and protein secretion.
25(OH)D vs Control 25(OH)D+PBA vs Control 25(OH)D+PBA vs PBA
Analyte Fold change1 P Fold change1 P Fold change1 P
mRNA CYP24A1 2922.85 2.29 x10-7 9740.72 6.29 x10-10 4260.58 5.94 x10-9
CAMP 54.01 0.0002 195.63 0.0003 105.96 9.70 x10-5
IL37 12.6 2.41 x10-5 35.91 1.22 x10-6 7.25 5.00 x10-5
IL36G 8.85 0.0014 14.4 0.0009 2.84 0.0222
TREM1 5.27 8.54 x10-5 6.92 1.26 x10-5 3.98 0.0002
NOD2 2.45 0.0049 - ns - ns
PROC - ns 9.09 1.24 x10-5 -3.74 0.0067
ARG1 - ns 3.62 0.0384 2.22 0.0342
LTF - ns 3.45 0.0075 - ns
IL1B - ns 3.19 0.0395 - ns
IL12A - ns - ns -3.86 0.0109
IL10 - ns -1.56 0.0372 - ns
IFNG - ns -3.24 0.0563 - ns
VDR -2.09 0.0036 -1.70 0.0152 -2.35 0.0011
TNF -2.56 0.0136 -2.04 0.0571 - ns
CXCL9 -4.16 0.0011 -8.94 0.0394 - ns
CYP27B1 -6.15 0.0033 -3.17 0.001 -2.56 0.0022
CASP1 -5.78 1.70 x10-5 - ns -3.00 0.001
CXCL7 -8.76 0.0015 -25.67 0.0001 -3.96 0.0062
CXCL10 -9.54 0.0031 -33.02 0.0027 -10.67 0.0162
Protein IL-1B 2.84 0.0012 - ns - ns
CXCL9 - ns -2.31 0.0299 - ns
CXCL10 -1.69 0.0172 -2.43 0.0027 -2.63 0.0045
CCL2 -5.00 0.0004 -23.13 0.0001 -2.77 0.0156
CCL5 - ns - ns -2.21 0.0157
1Fold change and p-value from t-test for GLM on indicated samples at 24 and 72 hrs with adjustment for subject ID (repeated measures, n = 3–4) and
time; non-signiﬁcant (ns) if false discovery rate (q-value) >0.1
doi:10.1371/journal.ppat.1005007.t002
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IL36, IL37 and TREM1] and two were inhibited [CXCL7, CYP27B1]), two were regulated in an
opposite direction to PBA (CASP1 and VDR) and four (CXCL9 (OMIM 601704), CXCL10
(OMIM 147310), NOD2 (OMIM 605956), TNF (OMIM 191160)) were not significantly regu-
lated by PBA monotherapy (Tables 1 and 2). Adding 25(OH)D3 in the presence of PBA
enhanced the response of eight 25(OH)D3-regulated genes: five (CAMP, CYP24A1 (OMIM
126065), IL36, IL37, TREM1) were synergistically induced, with the combined effect of co-
treatment greater than an additive combination of individual effects, and three chemokines
CXCL7, and IFNγ-inducible CXCL9 and CXCL10 were all further inhibited by combined treat-
ment, despite the fact that PBA only showed a trend towards inhibition of CXCL9 and CXCL10
during monotherapy (Fig 4B and Table 2). IFNG was also inhibited by co-treatment, but there
was no independent effect of PBA or 25(OH)D3 on IFNG expression (Tables 1 and 2). We also
analysed the effect of co-treatment on uninfected cells and near identical patterns of synergism
were observed for induced genes, except for the CXC chemokines which were only inhibited
during infection (S7 Fig).
Of the two genes which were differentially regulated by PBA and 25(OH)D3 monotherapies,
CASP1 showed an intermediate expression between the two therapies during co-treatment
with the effect dominated by 25(OH)D3, such that expression of CASP1 was inhibited during
co-treatment. Furthermore, 25(OH)D3 attenuated PROC induction by PBA, despite not having
a significant effect of PROC during monotherapy (Fig 4B and Table 2).
To determine whether the synergistic effect of PBA on 25(OH)D3 gene expression was
potentially associated with increased 1,25(OH)D3 production or activity, the expression of
CYP27B1 and VDR was also assessed, respectively. The inhibition of CYP27B1 and VDR
expression by 25(OH)D3 was very moderately attenuated by co-treatment with PBA (Fig 4B
and Table 2), suggesting PBA may enhance the response to 25(OH)D3 through increased VDR
signalling, particularly as PBA monotherapy induces VDR.
PBA and 25(OH)D3 have limited synergistic effect on cytokine and
chemokine secretion
We next investigated whether co-treatment with PBA and 25(OH)D3 had a synergistic effect
on cytokine/chemokine secretion in supernatants from the sameMtb-infected MDM by apply-
ing the same GLM analysis technique to secretion data as for expression data. Only three ana-
lytes of the 30 investigated were identified to be significantly regulated by 25(OH)D3 and only
three were regulated during co-treatment (Table 2). CCL2 secretion, which was significantly
inhibited by PBA (Fig 3D), was also inhibited by 25(OH)D3 and synergistically inhibited dur-
ing co-treatment (Fig 4C). Reflecting gene expression results, secretion of CXCL9 and CXCL10
was inhibited during co-treatment despite only CXCL10 being inhibited by 25(OH)D3 mono-
therapy, while neither was inhibited by PBA monotherapy. Conversely, an opposing effect of
co-treatment was observed for CCL5 and IL-1β, 25(OH)D3 attenuated CCL5 induction by
PBA, while PBA attenuated 25(OH)D3 induction of IL-1β (Fig 4C, Table 2).
PBA and 25(OH)D3 influence transcript abundance via different
pathways
In an epithelial cell line, mitogen-activated protein kinase (MAPK) signalling via JNK (OMIM
601158) and ERK1/2 (OMIM 601795/176948) pathways has been shown to regulate PBA-
induced CAMP expression [26]. We therefore investigated whether PBA regulated synergistic
25(OH)D3 gene expression in macrophages via the same MAPK pathways and whether it also
utilised these pathways to regulate non-vitamin D-associated genes. MAPK pathway inhibitors
for p38 kinase (SB202190), JNK (SP600125) and ERK1/2 (U0126) were added to MDM 4 hrs
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Fig 4. PBA and 25(OH)D3 synergistically and independently modulate MDM response toMtb infection. (A) Heirachical clustering of the 20 genes
identified to be differentially regulated by at least one of the three comparisons: 25(OH)D3 (red) vs control (black), co-treatment (purple) vs control (black) and
co-treatment vs PBA (blue) (Table 2). Gene expression of 25(OH)D3 treated cells clusteres with co-treated samples, while PBA-treated samples cluster
seperately. The patterns of expression also cluster according to time of sampling, with the R-statistic, representing the degree of difference for each
comparison. Heirachcal clustering of genes (left hand tree dendogram) displays the correlation between regualted genes. (B) MDM gene expression during
Mtb-infection over 72 hours. (C) MDM protein secretion 72 hrs post-infection. Mean ± SD, n = 3–4; P-values from t-test for GLM, with adjustment for donor
variation and time of treatment with false discrovery rate q<0.1 (Tables 1 and 2); *, P<0.05; **, P<0.01; ***, P<0.001.
doi:10.1371/journal.ppat.1005007.g004
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post-infection, for 1 hr prior to addition of PBA ± 25(OH)D3 and gene expression analysed 24
hrs post-treatment (Fig 5). Synergistic induction of CAMP and CYP24A1 was completely
inhibited by p38 kinase inhibition, and only partially by ERK1/2 and JNK inhibition. P38
kinase inhibition also had the greatest effect on attenuating IL37 induction by 25(OH)D3,
while ERK1/2 inhibition had the greatest effect on attenuating PBA and co-treatment induc-
tion of IL37. However, for TREM1, while p38 inhibition prevented induction by 25(OH)D3
and ERK1/2 inhibition somewhat attenuated PBA, ERK1/2 inhibition also attenuated expres-
sion in control cells and none of the MAPK inhibitors prevented synergistic induction, com-
pared to control.
Analysis of the two genes differentially regulated by PBA and 25(OH)D3, CASP1 and
PROC, indicated very different patterns for the two treatments: CASP1 induction by PBA was
attenuated by all three pathways although the most via p38, while p38 also attenuated CASP1
inhibition by 25(OH)D3. Conversely, PROC expression was only moderately suppressed by
ERK1/2 inhibition, during PBA and co-treatment, again not to untreated levels, and JNK inhi-
bition actually led to increased expression by PBA and co-treatment (Fig 5).
Finally, when we investigated genes independently regulated by PBA, we found that even
though IL1B, LTF and NLRP3 expression can be inhibited via at least one of the signalling
pathways, the induction by PBA of IL1B and LTF occurred even when these pathways were
suppressed and only NLRP3 induction was partially attenuated by inhibition of ERK signalling
(Fig 5). These results indicate that the vitamin D-independent mechanism of PBA-regulated
gene expression is predominantly mediated via pathways other than MAPK signalling.
25(OH)D3 and PBA have independent and additive anti-mycobacterial
effects
Finally, as we found a significant synergistic effect of PBA on 25(OH)D3 induction on CAMP
expression (Fig 5B), we investigated whether co-treatment with PBA enhanced 25(OH)D3-
dependent restriction ofMtb growth via cathelicidin production over 7 days of culture, treating
macrophages 4 hrs post-infection with either mono- or dual-therapy. Consistent with dose
response experiments (Fig 2D), 4mM PBA restricted growth after 7 days (2.8-fold growth,
compared to 7.9-fold growth in untreated cells, P = 0.0012), treatment with 25(OH)D3 alone
resulted in 6.9-fold growth (although not significantly different to control), while co-treatment
resulted in 2.4-fold growth (P = 0.0017), and there was no synergistic effect compared to PBA
monotherapy (Fig 6A). We also confirmed by checkerboard Alamar Blue assay that there was
no direct effect of 25(OH)D3 on in vitro Mtb growth, in the absence or presence of PBA (S8
Fig).
The fact that there was no significant effect of 25(OH)D3 monotherapy or synergistic reduc-
tion inMtb growth, despite the 100-fold synergistic induction of CAMP expression, suggested
that the antimicrobial action of cathelicidin may not have been activated in our in vitromodel.
Activation requires proteolytic processing of the translated pro-LL-37 into active LL-37 by pro-
teinase 3 (PR3) [8]. We therefore investigated expression of PRTN3 (translated into PR3) in
MDM compared to whole blood (WB), PBMC, MN and infected MDM treated ± 25(OH)D3
and PBA. We found MDM down-regulated PRTN3 6-15-fold (P<0.038) compared to PBMC,
WB and MN and that PRTN3 was further down-regulated over 72hr of infection (Fig 6B). We
therefore added PR3 to infected MDM during treatment with 25(OH)D3 ± PBA to determine
whether LL-37 activation was required for 25(OH)D3-mediatedMtb growth inhibition. PR3
addition significantly inhibitedMtb growth in 25(OH)D3-treated MDM to the same level seen
with PBA co-treatment, while addition of PR3 during co- treatment further reducedMtb
growth (Fig 6C). These findings suggest that 25(OH)D3 and PBA restrictMtb growth in MDM
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via a common cathelicidin-mediated pathway and that PBA also inhibits growth independantly
of cathelidicin.
Discussion
PBA is currently used to treat a range of clinical disorders, due to its pleiotropic effects on cellu-
lar differentiation, proliferation and as a prodrug for phenyl acetate. Here we show that clini-
cally attainable concentrations of PBA 1) restrict intracellular and in vitro growth of
Mycobacterium tuberculosis, 2) inhibitMtb phagocytosis by PBMC and MDM, 3) induce anti-
microbial and inflammatory pathway genes, including LTF, PROC, and the inflammasome cas-
cade by MDM and 4) augment 25(OH)D3-mediated anti-mycobacterial and anti-
inflammatory effects. Our findings suggest that combined PBA and vitamin D may prove an
enhanced adjunct therapy to intensive-phase anti-TB treatment; mediated by both broad host-
directed and bacterial-directed actions that have the potential to enhance bacterial control as
well as resolve lung pathology through broad-ranging anti-inflammatory effects.
Fig 5. PBA synergistically regulates 25(OH)D3-mediated gene induction via MAPK signalling pathways.MDMwere incubated for 1hr with 20μM of
MAPK signalling inhibitors for p38 (SB202190), JNK (SP600125) and ERK1/2 (U0126) pathways, prior to addition of 4mM PBA (blue), 100nM 25(OH)D3
(red) or co-treatment (purple) and gene expression analysed 24 hrs post-treatment. Mean ± SD, n = 3–4; 2-way ANOVA with Dunnett’s multiple comparisons
test: *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.
doi:10.1371/journal.ppat.1005007.g005
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PBA has previously been suggested as an antimicrobial agent for the treatment of respira-
tory infections, due to its ability to reverse the inhibition of expression of the rabbit CAMP
homologue, CAP-18, in lung and trachea epithelium during Shigella infection and induce pro-
CAP-18 processing [35, 36]. For the first time we show that PBA not only induces CAMP
expression in human macrophages duringMtb infection, independently and synergistically
with physiological concentrations of 25(OH)D3, but it also synergistically enhanced expression
of the most highly induced vitamin D-regulated gene CYP24A1 and three genes previously not
known to be regulated by vitamin D: IL36G, IL37 and TREM1 (Fig 4). All three have immuno-
modulatory properties and therefore may be key regulators of yet unrecognised vitamin D-
mediated immune modulation.
Fig 6. PBA restricts intracellularMtb growth independently of 25(OH)D3. (A) Intracellular growth ofMtb in MDM treated 4 hrs post-infection with 4mM
PBA, 100nM 25(OH)D3 (25D) or co-treatment. (B) Expression of proteinase 3 (PRTN3) in whole blood (WB), PBMC and MN compared to MDM ±Mtb
infection ± 25(OH)D3 or co-treatment (Co). (C) Treatment of MDM 4 hrs post-infection in the presence or absence of human neutrophil proteinase 3 (PR3).
Median ± IQR (A,C) or Mean ± SD (B); n = 5–10; repeated measures 1-way ANOVA with Bonferroni’s multiple comparisons test (A, B) or Wilcoxon matched-
pairs test (C): *, P<0.05; **, P<0.01, ns, non-significant.
doi:10.1371/journal.ppat.1005007.g006
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Both members of the IL-1 superfamily, IL-36G and IL-37 have opposing effects, being pro-
and anti-inflammatory, respectively [37, 38]. We found that IL36G was induced byMtb infec-
tion while IL37 was not. Furthermore, both genes were synergistically induced by PBA and 25
(OH)D3, irrespective ofMtb infection, indicating treatment alone was required for induction.
Our observations are the first reported evidence that vitamin D signalling increases IL37
transcript levels. IL-37 has recently been identified as a natural innate inhibitor, suppressing
macrophage TLR-induced cytokine and chemokine secretion of IL-1α (OMIM 147760), IL-1β,
IL-6 (OMIM 147620), IL-12, G-CSF (OMIM 138970), GM-CSF (OMIM 138960), and TNF by
up to 98%, without regulating IL-10 or IL-1RA (OMIM 147679). Mature IL-37 has been shown
to traffic to the nucleus after caspase-1 processing where it complexes with Smad-3 to facilitate
TFGβmediated cytokine suppression, as well as reducing phosphorylation of p38 MAPK, and
STAT1-4 [38]. IL-37 may therefore be an additional mediator by which vitamin D elicits its
broad anti-inflammatory effects
TREM1 (triggering receptor on myeloid cells-1) regulates inflammation by modulating TLR
and NACHT-LRR (NLR) signals [39, 40]. While TREM1 is constitutively expressed by myeloid
cells, the level of induction influences the outcome of infection, such that in a mouse model of
sepsis, moderate silencing of TREM1 improved survival, but near-complete silencing reduced
neutrophil oxidative burst and increased mortality [41]. We found that TREM1 was moder-
ately induced byMtb infection and it was synergistically induced by 25(OH)D3 and co-treat-
ment with PBA, irrespective of infection (Figs 4 and S4).
Through the use of MAPK inhibitors we determined that PBA-25(OH)D3 synergistic regu-
lation was mediated particularly via p38 or ERK1/2 signalling, but differed by gene, and that
the synergistic regulation of TREM1 was MAPK-independent. We also found that PBA alone
induced VDR expression, and a recent study in epithelial cells has shown VDR knockdown pre-
vents CAMP induction by PBA-25(OH)D3 co-treatment, indicating VDR is vital to this syner-
gistic regulation [42].
Surprisingly, despite the greater than 50-fold induction of CAMP expression by 25(OH)D3
which was synergistically induced by PBA co-treatment, we found a trend but no significant
effect of 25(OH)D3 onMtb growth in our MDMmodel. We found MDM significantly down-
regulate PRTN3 expression and that exogenous PR3 is required to activate 25(OH)D3-depen-
dant growth suppression in MDM. In vivo, activated neutrophils, recruited by the infected
macrophages, could be a source of exogenous PR3. However, lack of vitamin D-mediated anti-
microbial activity in vivomay be due to unavailability of PR3 to macrophages and future stud-
ies should investigate the distribution of PR3 in human TB lung tissues.
We also found that PR3 enhanced growth suppression during co-treatment, which was
dominated by PBA in the absence of PR3 to activate cathelicidin (Fig 6). This suggests that the
synergistic anti-Mtb effects of PBA and 25(OH)D3 are likely partially mediated via cathelicidin,
but PBA also had cathelicidin-independent effects onMtb growth.
We found that growth restriction by PBA was both MDM-dependent and-independent.
Clinically attainable concentrations of PBA completely inhibitedMtb growth in broth, with a
reduced MIC99 under acidic conditions, whenMtb was inoculated into PBA-containing
medium at low density. Moreover, when high density exponentially growing cultures were
treated with PBA, growth was considerably restricted and this growth inhibition was main-
tained even when PBA was removed, suggesting that PBA may interfere with a structural com-
ponent required for replication, as the defect was long-lived. This theory is supported by the
phenotypic change of PBA-treated bacilli observed by confocal microscopy.
While it may be suggested that the intracellular restriction ofMtb growth was due entirely
to the direct effect of PBA onMtb, we made a number of observations suggesting otherwise: 1)
PBA modulates macrophage function independently of infection within 24–48 hrs; 2) pre-
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treatment ofMtb with PBA did not significantly inhibit 4 hrs uptake or 7 day intracellular
growth; 3) significant inhibition of intracellularMtb growth was only observed after 7 days of
treatment, whilst growth in broth was inhibited after 2 days. The last observation may also be
explained by theMtb target of PBA only being expressed intra-phagosomally after a few days
of infection, with acidification of the phagosome potentially enhancing the direct action of
PBA. However the fact remains that PBA modifies infected-macrophage function more rapidly
than the effect onMtb is observed, suggesting a cell-mediated effect on growth also exists.
Consistent with PBA inhibitingMtb growth via an MDM-dependant mechanism, we found
PBA induced expression of LTF, encoding the antimicrobial agent and iron chelator lactofer-
rin. Lactoferrin has been shown to enhance IFNγ-mediated killing ofMtb in MDM and oral
administration of lactoferrin toMtb-infected mice decreased lung CFU and inflammation [32].
PBA also induced expression of PROC, encoding the anti-inflammatory and anti-coagulant
Protein C. Activated protein C (aPC) has been shown in vitro to suppress expression of the p50
and p52 subunits of NF-κB, blocking NF-κB signalling [33], increasing production of IL-10
and TGFβ [43] and in vivo, blocking neutrophil chemotaxis and adhesion to vascular endothe-
lial cells, resulting in decreased lung infiltration of neutrophils in an LPS-induced lung injury
model [44]. The recent interest in neutrophils as a primary mediator of pathology in active TB
suggests PBA-induced regulation of PROCmay enhance resolution of pathologic inflammation
during TB treatment [45]. The anti-coagulation effect of PROC may also reduce disseminated
intravascular coagulation (DIC), which has a high mortality rate in TB patients [46].
Four genes in the inflammasome pathway which may augment the antimicrobial activity of
macrophages were also significantly induced by PBA [47]. Surprisingly, despite CASP1, IL1B,
NCF4 and NLRP3 expression being induced by PBA, IL-1β secretion was not. However, this
may be because IL-37, which is known to inhibit IL-1β secretion [38], was simultaneously
induced by PBA. In support of this theory, co-treatment with PBA attenuated the secretion of
IL-1β induced by 25(OH)D3, at the same time as synergistically inducing IL37 expression. Fur-
ther research is required to clearly delineate these interactions.
The role of MAPK signalling in the vitamin D-independent transcriptional effects of PBA
was also investigated; although MAPK inhibition partially attenuated expression of LTF, PROC
and inflammasome-associated genes, it did not prevent their PBA-mediated induction. Future
work will investigate the role of PBA as a HDACi in regulating the expression of these genes.
Our findings are limited by the fact that we have not yet confirmed the direct and cell-medi-
ated antimicrobial mechanisms of PBA, although we have observations that indicate PBAmay
be acting on the cell wall. Through the development of PBA-resistant mutants, transposon muta-
genesis libraries and macrophage knockdown of LTF, future research will more clearly delineate
these mechanisms. Moreover, while we investigated the effect of PBA onMtb uptake and growth
in PBMC we did not characterise the transcriptional effect of PBA on leukocytes other than mac-
rophages. Recent work has shown that PBA and 1α,25(OH)2D3 co-treatment of MN during dif-
ferentiation into dendritic cells (DC) promotes the development of a CD14+/CD1a- DC subset
which produces enhanced levels of cathelicidin and reactive oxygen species (ROS) and which
have enhanced anti-Staphylococcus aureus activity [48]. It is therefore likely that vitamin D and
PBA have additional cell-mediated effects on the TB immune response, yet to be elucidated.
Together, our results suggest that PBA treatment could independently restrictMtb growth
in vivo as well as enhance the antimicrobial and anti-inflammatory effects of vitamin D, such
that combined PBA and vitamin D therapy during anti-TB treatment may be superior to vita-
min D alone. Clinical trials also need to be conducted to evaluate the efficacy of adjunctive
PBA in reducing time to culture conversion, independent of vitamin D. However, the com-
bined effect of these two compounds together on anti-microbial and particularly on anti-
inflammatory molecules, which are proposed to have a significant benefit on reducing
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morbidity in TB patients, suggest this combined adjunct therapy might be of greater benefit
than either compound alone. The fact that the first Phase 2 trial to investigate the in vivo effi-
cacy of this combined therapy was recently completed in Bangladesh, is therefore timely [29].
Our findings of broad and synergistic action of these two compounds will have particular rele-
vance to the interpretation of results from this trial, which will also provide the first in vivo
study of PBA as an adjunctive therapy for TB.
Methods
Ethics statement
Human leukocytes were obtained from healthy volunteers (n = 21). PBMCs from healthy
donors were obtained from buffy coats processed by the National Blood Services, Colindale,
UK, or heparinised whole blood from healthy volunteers following an explanation of the nature
and possible consequences of the study and written informed consent. Ethical approval was
received from the Human Research Ethics Review Board of the Faculty of Health Sciences,
University of Cape Town, and UKMRC National Institute for Medical Research.
Mtb culture
MtbH37Rv frozen stocks were prepared as previously described [49] (S1 File). For PBA treat-
ment experiments,Mtb was inoculated from frozen stocks into 7H9/ADC/0.01% tyloxypol and
grown in rolling culture at 37°C. Ten-fold serial dilutions of exponential phase culture were
plated on 7H11/OADC agar containing 0-4mM PBA and incubated at 37°C with CFU moni-
tored over 21 days. To analyse the effect of PBA in liquid culture, exponential phase cultures
were sub-cultured to OD600 0.01 and after 4 days growth (Average OD600 of 0.56) PBA was
added to at final concentrations of 0.4-4mM. OD600 was monitored over 10 days. Two and six
days after addition of PBA, 10-fold serial dilutions (in PBS/0.05% Tween 80) of each culture
were plated for CFU analysis. After 10 days of treatment, each rolling culture was pelleted,
washed twice in PBS/0.01% tyloxypol and resuspended in medium without PBA to OD600 0.1
and culture continued for a further 8 days, monitoring OD600. PBA supplemented media and
an aliquot of each 10-day PBA-treated culture was twice filter sterilised and pH was measured
(SevenEasy conductivity meter, Mettler Toledo). For the Alamar Blue (Invitrogen) reduction
checkerboard assaysMtb was inoculated in 96-well plates at OD600 0.0002 in 7H9/ADC con-
taining 2-fold serial dilutions of PBA, 25(OH)D3 or HCl. After 13 days of culture, a tenth of the
volume of Alamar Blue was added and colour formation observed after overnight incubation.
To determine the effect of PBA pre-treatment ofMtb on the outcome of MDM infection,Mtb
stocks were prepared by treating an exponential phase culture at 0.5 OD600 ± 4mM PBA for 4
days. Cultures were pelleted, washed twice in PBS/0.05% and resuspended in 7H9, OD600 deter-
mined and then an infection stock prepared in RPMI for addition to MDM at final OD600 0.005
(0.2% 7H9). Infection stocks were titrated and plated for CFU, confirming MOI 1:1 (S3 Fig).
For imaging, GFP-H37Rv was grown to exponential phase in 7H9/0.05% Tween 80 with
25μg/ml kanamycin, subcultured to 0.18 OD600 and grown ± 4mM PBA for 4 days. 1ml of cul-
ture was fixed in 6% PFA for 45min, pelleted, washed in PBS and resuspended in water or
Mowiol for mounting under coverslip. Slides were viewed on an Axiovert 200M LSM 510 Meta
confocal microscope (Zeiss) and images analysed in Zen Blue 2012 software (Zeiss).
Culture of PBMC and MDM
PBMC were prepared on a Ficoll-Paque density gradient and used immediately without cryo-
preservation. PBMC were cultured at 5x105 cells/48-well in RPMI 1640 (containing 10mM
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sodium pyruvate, 50mM glutamine and 10% foetal calf serum (FCS)) for 3 days prior to infec-
tion at 37°C/5% CO2. To generate MDM, MN were obtained from PBMC by CD14
+ magnetic-
-activated cell sorting (MACS, Miltenyi). MN were cultured at 2x106 cells/6-well in RPMI
supplemented with 5ng/ml GM-CSF for 6 days. Following differentiation, MDM were
detached and plated at 9x104 cells/96-well in RPMI and rested at 37°C for one hour before
infection.
PBMC were infected at a multiplicity of infection (MOI) normalized to average MN count
(10% PBMC), giving MOI bacillus:PBMC 0.1:1. At the time of PBMC infection a 2-fold serial
dilution of PBA (0-8mM) was added to cultures. After 4 and 96 hrs, PBMC were pelleted by
centrifugation, washed twice with PBS, lysed for 30min with H2O/0.05% Tween 80 and 5-fold
serial dilutions of lysate plated for intracellular CFU.
MDM were infected (MOI 1:1) for 4 hrs, extracellularMtb removed by washing cells twice
with PBS and then cultured in RPMI containing a 2-fold serial dilution of PBA (0.5-4mM), a
10-fold serial dilution of 25(OH)D3 (10-1000nM), 4mM PBA+100nM 25(OH)D3, or vehicle
control (0.01% EtOH) for up to 7 days. To determine the effect of PBA on MDM phagocytic
function, MDM were treated for 48 hrs with 4mM PBA, washed three times with PBS, infected
withMtb and intracellularMtb plated for CFU 4 hrs post-infection.
Additional 25(OH)D3 and co-treated cultures were also supplemented with 10μg/ml PR3 at
the time of treatment and CFU monitored 7 days post-infection. For MAPK signalling inhibi-
tion, MDM were pre-incubated for 1hr with 20μM SB202190, SP600125, U0126 (Sigma) or
vehicle control (0.08% DMSO), prior to and during stimulation.
Flow cytometry
MDMwere detached after 48 hrs treatment with PBA, by incubating in Acutase (Invitrogen) at
37°C for 30min, washed twice with PBS, and suspended in PBS/5% FCS. Cells were incubated
with either monoclonal mouse anti-human CD35/FITC, CD11c/PE, CD16/PE.Cy5, CD11b/
APC conjugated antibodies or respective IgG-conjugated antibodies (BD Bioscience) in the
dark at 4°C for 30 min. Cells were washed, resuspended in CytoFix/Perm (BD Bioscience) for
20 min at 4°C and then washed twice and resuspended in PBS/5% FCS. An aliquot of unfixed
cells were also incubated with propidium iodide. Ten thousand events were analysed for each
sample by immunofluorescence using flow cytometry (BD FACSCalibur). Results were ana-
lysed using Flow Jo (version 10).
RT-PCR arrays
RNA was extracted fromMDM samples following homogenisation in TRI Reagent (Sigma-
Aldrich) and storage at -80°C until batch-processed. RNA was extracted with chloroform in
phase lock tubes (5 Prime) following the manufactures protocol, using linear poly-acrylamide
(Ambion) as a carrier protein and suspension in RNase-free H2O (Sigma). RNA integrity and
concentration was determined on a NanoDrop 2000 (Thermo Scientific) and by running on a
1.5% TAE agarose gel. 150ng RNA was reverse transcribed using the RT2 First Strand Kit
(SABiosciences) which includes a genomic DNA (gDNA) elimination step. cDNA was ana-
lysed using 384-well RT2 Profiler Custom PCR Arrays (SABiosciences) which included 28
genes involved in innate and adaptive immunity (CAMP, CASP1, CXCL7, CXCL8, CXCL9,
CXCL10, IFNB1 (OMIM 147640), IFNG, IL1B, IL6, IL10, IL12A, IL12B (OMIM 161561),
IL23A (OMIM 605580), IL36G, IL37, LTF, NOD2, NCF4, NLRP3, PGLYRP1 (OMIM 604963),
PROC, ARG1, TNF, TREM1) and vitamin D metabolism (CYP24A1, CYP27B1, VDR), plus the
house-keeping (HK) gene RPL13A (UniProt P40429) and three control reactions to monitor
gDNA contamination and reverse transcription efficiency on the Roche 480 platform. A
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comparison of 5 HK genes across all treatment and infection conditions indicated that RPL13A
was the most stable (S9 Fig). Fold induction was calculated from Ct values using the ΔΔCt
method normalising all samples to baseline untreated.
RT-PCR
For PRTN3 expression analysis RNA was extracted from 1 million PBMC and MN following
homogenisation in TRI Reagent (as for MDM) and from 3ml whole blood collected in Tempus
tubes and extracted with the Tempus Spin RNA Isolation Kit (Life Technologies) and storage
at -80°C. 100ng RNA was reverse transcribed using SuperScript VILO cDNA synthesis kit (Life
Technologies) and real-time RT-PCR was performed using primers (S1 Table) for PRTN3 and
GNB2L1 (OMIM 176981, HK) with Fast SYBR Green chemistry using 10% cDNA on a Quant-
Studio 7 (Life Technologies). Stable expression of GNB2L1 across all sample types was con-
firmed by Ct comparison (S10 Fig). Expression levels of PRTN3 were normalised to that of
GNB2L1 by ΔΔCt and fold change to mean MDM expression calculated.
For CAMP, CYP27B1 and CYP24A1 expression analysis (primer sequences in S1 Table)
100ng RNA fromMDMwas reverse transcribed using High Capacity cDNA synthesis kit (Life
Technologies) and real-time RT-PCR was performed with Fast SYBR Green chemistry), using
10% cDNA on an ABI 7500 fast (Life Technologies). Absolute quantification was carried out
using standard curves generated by serial dilution of target amplicon-containing plasmids
(pGEM-T easy, Promega), to cover up to 5 logs of amplicon copy number per microliter and
absolute copy number normalized to GNB2L1.
Luminex
Supernatants were harvested fromMDM infection experiments 24 and 72 hrs post-infection
and double sterilized through 0.2uM PVDF filters (Corning). Concentrations of IL-1β, IL-1RA,
IL-2 (OMIM 147680), IL-2R, IL-4 (OMIM 147780), IL-5 (OMIM 147850), IL-6, IL-7 (OMIM
146660), IL-10, IL-12 (p40/p70), IL-13 (OMIM 147683), IL-15, IL-17 (OMIM 603149), G-CSF,
GM-CSF, IFNα, IFNγ, TNF, CXCL8, CXCL9, CXCL10, CCL2, CCL3, CCL4, CCL5, CCL11
(OMIM 601156), EGF (OMIM 131530), FGFβ (OMIM 134920), HGF (OMIM 142409) and
VEGF (OMIM 192240) were quantified using a human 30-plex bead immunoassay panel
(Invitrogen) and analysed on a BioPlex 200 platform (Bio-Rad). Analytes at the limit of detec-
tion were given the value zero. Concentrations from infected samples were baseline corrected
by subtracting the concentration of uninfected samples prior to statistical analysis.
Statistical analysis
Cells from all donors received all treatments (paired analyses) and RNA, culture supernatants
and CFU where matched for donor where multiple analyses where conducted under the same
infection conditions, where possible. Infection experiments were performed on up to 10
donors, in triplicate for CFU and in duplicate for RNA and secreted protein analysis.Mtb cul-
ture experiments were done in duplicate and repeated. Samples were assigned a numerical de-
identifier prior to analysis and decoded after raw data was captured. Statistical significance was
tested using paired t-test of single treatment analysis, Wilcoxon match-pairs for non-paramet-
ric data, 1way-ANOVA, with Bonferroni multiple comparison test for dose response analysis
at a single time point or 2way-ANOVA, with Dunnett's multiple comparison test for dose
response analysis over multiple time points. GLM, PCA and hierarchical clustering were con-
ducted on gene expression and protein secretion data using Qlucore Omics Explorer 2.2 (Qlu-
core AB, Lund, Sweden) (S1 File).
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Supporting Information
S1 File. Materials and methods.Mtb Stock Preparation, treatments and statistical analysis.
(DOCX)
S1 Fig. Multiple examples of confocal images ofMtb strain GFP-H37Rv treated with and
without PBA. (A)Mtb treated with PBA are often found bound along the entire shaft of neigh-
bouring bacilli, forming lined-up clusters, unlike untreated cultures (B) which had single bacilli
or overlapping bacilli when in clusters. GFP-expression is in green, and phase contrast image
in grey, with overlaid images on the right.
(TIF)
S2 Fig. Effect of PBA on the pH of culture medium (7H9 or RPMI) before or afterMtb
infection. There was no effect of PBA on the pH of any medium.
(TIF)
S3 Fig. Colony forming units (CFU) of infection stock made fromMtb treated with/without
4mM PBA for 4 days prior to infection and 4 hrs uptake by macrophages. There was no dif-
ference in CFU of the infection stock (A) or uptake by macrophages (B). Mean ± SD, n = 3 (A)
and n = 4 donors, in triplicate (B); Paired t-test, all non-significant.
(TIFF)
S4 Fig. MDM gene expression in response to treatment with PBA serial dilution. During
Mtb infection of MDM PBA regulated gene expression in a dose-dependant manner, mean,
n = 2.
(TIF)
S5 Fig. MDM secretion in response to treatment with PBA serial dilution. DuringMtb
infection PBA regulated MDM secretion in a dose-dependant manner. Secretion is normalised
by subtracting uninfected samples. Mean ± SD; n = 2; 1way-ANOVA, with Dunnett’s multiple
testing; , P<0.05; , P<0.01.
(TIF)
S6 Fig. MDM expression in response to treatment with 25(OH)D3 serial dilution. Expres-
sion of vitamin D regulated genes CAMP, CYP24A1 and CYP27B1 by uninfected MDM and
cells infected withMtbH37Rv, for 4 hrs prior to treatment, Mean ± SD, n = 2. Differences
between samples were analysed for log10 transformed data by repeated-measured 2way
ANOVA, with Dunnett’s multiple comparison test; , P< 0.05; , P< 0.01; , P< 0.001;
, P< 0.0001.
(TIFF)
S7 Fig. Uninfected MDM gene expression in response to treatment with PBA and 25(OH)
D3. PBA + 25(OH)D3 synergistically induced expression of CYP24A1, CAMP, IL36G, IL37 and
TREM1, while inhibiting expression of CYP27B1 in uninfected MDM treated 4hrs after plating.
CXCL7, CXCL9 and CXCL10 were not significantly regulated in uninfected MDM. Untreated
control (black); 4mM PBA (blue); 100nM 25(OH)D3 (red); co-treatment (purple). Mean ± SD,
n = 3, in duplicate.
(TIF)
S8 Fig. Checkerboard Alamar Blue reduction assay measuring MIC99 of 25(OH)D3 in com-
bination with PBA. Two-fold serial dilutions of 25(OH)D (800nM-3.1nM) and for PBA
(4mM-0.13mM) showed that 25(OH)D3 does not affectMtb growth in this physiologial range
and has no effect on growth restiction by PBA. (A) 13 days growth and (B) 14 days growth, 16
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hrs after addition of Alamar Blue. Growth occurs in pink wells with visible whiteMtb pellets,
and no growth in blue wells. Red square indicates 100nM 25(OH)D3, the concentration used
during macrophage experiments.
(TIF)
S9 Fig. Analysis of the expression of house keeping (HK) genes in monocyte-derived mac-
rophages.MDMwere ±Mtb infection, 24 hrs or 72 hrs post-infection ± 4mM PBA
and ± 100nM 25(OH)D3 treatment. RPL13A was the most stably expressed across all condi-
tions. 150ng RNA was added to each cDNA reaction. Expression is represented as cycle thresh-
old (Ct), line indicates median ± IQR, n = 34.
(TIF)
S10 Fig. Analysis of the gene expression cycle time (Ct) of PRTN3 vs the house keeping
gene GNB2L1. Comparison between whole blood (red), PBMC (dark pink) and monocytes
(light pink) vs MDM ±Mtb infection for 4, 24 or 72 hrs (black). Line indicates median, n = 3–5
donors.
(TIFF)
S1 Table. Primers used for real-time RT-PCR.
(XLSX)
Acknowledgments
We thank all healthy donors who contributed blood for this work. Atica Moosa for providing
GFP-H37Rv and Dirk Lang and Susan Cooper from the UCT confocal microscopy facility.
Author Contributions
Conceived and designed the experiments: AKC RJW ARM. Performed the experiments: AKC.
Analyzed the data: AKC. Contributed reagents/materials/analysis tools: RJW. Wrote the paper:
AKC. Reviewed and edited the manuscript: RJW ARM.
References
1. World Health Organisation. Global Tuberculosis Report. 2014. http://www.who.int/tb/publications/
global_report/en/.
2. Barnes PF, Leedom JM, Chan LS, Wong SF, Shah J, Vachon LA, et al. Predictors of short-term progno-
sis in patients with pulmonary tuberculosis. J Infect Dis. 1988; 158(2):366–71. PMID: 3403993
3. Elkington PT, D'Armiento JM, Friedland JS. Tuberculosis immunopathology: the neglected role of
extracellular matrix destruction. Sci Transl Med. 2011; 3(71):71ps6. Epub 2011/02/25. doi: 10.1126/
scitranslmed.3001847 PMID: 21346167
4. Wilkinson RJ. Host-directed therapies against tuberculosis. Lancet Respir Med. 2014; 2(2):85–7. Epub
2014/02/08. doi: 10.1016/S2213-2600(13)70295-9 PMID: 24503259
5. Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW, Skolimowska K, et al. IFN-gamma-
and TNF-Independent Vitamin D-Inducible Human Suppression of Mycobacteria: The Role of Cathelici-
din LL-37. J Immunol. 2007; 178(11):7190–8. PMID: 17513768
6. Rook GA, Steele J, Fraher L, Barker S, Karmali R, O'Riordan J, et al. Vitamin D3, gamma interferon,
and control of proliferation ofMycobacterium tuberculosis by human monocytes. Immunology. 1986;
57(1):159–63. PMID: 3002968
7. Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: vitamin D-mediated human antimicrobial activity
againstMycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol. 2007;
179(4):2060–3. PMID: 17675463
8. Sorensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, et al. Human cathelicidin,
hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3.
Blood. 2001; 97(12):3951–9. PMID: 11389039
Phenylbutyrate and Vitamin D: Dual Immunotherapy for Tuberculosis
PLOS Pathogens | DOI:10.1371/journal.ppat.1005007 July 2, 2015 21 / 23
9. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a
direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvi-
tamin D3. Faseb J. 2005; 19(9):1067–77. Epub 2005/06/30. PMID: 15985530
10. Yuk JM, Shin DM, Lee HM, Yang CS, Jin HS, Kim KK, et al. Vitamin D3 induces autophagy in human
monocytes/macrophages via cathelicidin. Cell Host Microbe. 2009; 6(3):231–43. doi: 10.1016/j.chom.
2009.08.004 PMID: 19748465
11. Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, et al. The human antimicrobial and chemo-
tactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte popula-
tions. Blood. 2000; 96(9):3086–93. PMID: 11049988
12. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-
mediated human antimicrobial response. Science. 2006; 311(5768):1770–3. PMID: 16497887
13. Wilkinson RJ, Llewelyn M, Toossi Z, Patel P, Pasvol G, Lalvani A, et al. Influence of vitamin D defi-
ciency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London:
a case-control study. Lancet. 2000; 355(9204):618–21. PMID: 10696983.
14. Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-
analysis. Int J Epidemiol. 2008; 37(1):113–9. doi: 10.1093/ije/dym247 PMID: 18245055
15. Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K, et al. Vitamin D accel-
erates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A.
2012; 109(38):15449–54. Epub 2012/09/06. PMID: 22949664
16. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, et al. High-dose vitamin D(3)
during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised
controlled trial. The Lancet. 2011; 377(9761):242–50. Epub 2011/01/11.
17. Krutzik SR, Hewison M, Liu PT, Robles JA, Stenger S, Adams JS, et al. IL-15 links TLR2/1-induced
macrophage differentiation to the vitamin D-dependent antimicrobial pathway. J Immunol. 2008; 181
(10):7115–20. Epub 2008/11/05. PMID: 18981132
18. Fabri M, Stenger S, Shin DM, Yuk JM, Liu PT, Realegeno S, et al. Vitamin D is required for IFN-
gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med. 2011; 3(104):104ra2.
Epub 2011/10/15.
19. Lea MA, Randolph VM, Hodge SK. Induction of histone acetylation and growth regulation in eryrthroleu-
kemia cells by 4-phenylbutyrate and structural analogs. Anticancer Res. 1999; 19(3A):1971–6. Epub
1999/09/02. PMID: 10470142
20. Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, et al. Phenylbuty-
rate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer
Res. 1996; 2(2):379–87. Epub 1996/02/01. PMID: 9816181
21. Bar-Ner M, Thibault A, Tsokos M, Magrath IT, Samid D. Phenylbutyrate induces cell differentiation and
modulates Epstein-Barr virus gene expression in Burkitt's lymphoma cells. Clin Cancer Res. 1999; 5
(6):1509–16. Epub 1999/07/02. PMID: 10389940
22. Li LZ, Deng HX, LouWZ, Sun XY, Song MW, Tao J, et al. Growth inhibitory effect of 4-phenyl butyric
acid on human gastric cancer cells is associated with cell cycle arrest. World J Gastroenterol. 2012; 18
(1):79–83. Epub 2012/01/10. doi: 10.3748/wjg.v18.i1.79 PMID: 22228974
23. Merzvinskyte R, Treigyte G, Savickiene J, Magnusson KE, Navakauskiene R. Effects of histone deace-
tylase inhibitors, sodium phenyl butyrate and vitamin B3, in combination with retinoic acid on granulo-
cytic differentiation of human promyelocytic leukemia HL-60 cells. Ann N Y Acad Sci. 2006; 1091:356–
67. Epub 2007/03/08. PMID: 17341628
24. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical chaperones
reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science.
2006; 313(5790):1137–40. Epub 2006/08/26. PMID: 16931765
25. Nguyen LN, Lopes LC, Cordero RJ, Nosanchuk JD. Sodium butyrate inhibits pathogenic yeast growth
and enhances the functions of macrophages. J Antimicrob Chemother. 2011; 66(11):2573–80. Epub
2011/09/14. doi: 10.1093/jac/dkr358 PMID: 21911344
26. Steinmann J, Halldorsson S, Agerberth B, Gudmundsson GH. Phenylbutyrate induces antimicrobial
peptide expression. Antimicrob Agents Chemother. 2009; 53(12):5127–33. Epub 2009/09/23. doi: 10.
1128/AAC.00818-09 PMID: 19770273
27. Kida Y, Shimizu T, Kuwano K. Sodium butyrate up-regulates cathelicidin gene expression via activator
protein-1 and histone acetylation at the promoter region in a human lung epithelial cell line, EBC-1. Mol
Immunol. 2006; 43(12):1972–81. Epub 2006/01/21. PMID: 16423398
28. Mily A, Rekha RS, Kamal SM, Akhtar E, Sarker P, Rahim Z, et al. Oral intake of phenylbutyrate with or
without vitamin D3 upregulates the cathelicidin LL-37 in humanmacrophages: a dose finding study for
Phenylbutyrate and Vitamin D: Dual Immunotherapy for Tuberculosis
PLOS Pathogens | DOI:10.1371/journal.ppat.1005007 July 2, 2015 22 / 23
treatment of tuberculosis. BMC PulmMed. 2013; 13:23. Epub 2013/04/18. doi: 10.1186/1471-2466-13-
23 PMID: 23590701
29. Raqib R. Clinical Trial of Oral Phenylbutyrate and Vitamin D Adjunctive Therapy in Pulmonary Tubercu-
losis in Bangladesh: a Pilot Study (NCT01580007). 2012. http://clinicaltrials.gov/show/NCT01580007.
30. Rampini SK, Selchow P, Keller C, Ehlers S, Bottger EC, Sander P. LspA inactivation inMycobacterium
tuberculosis results in attenuation without affecting phagosome maturation arrest. Microbiology. 2008;
154(Pt 10):2991–3001. Epub 2008/10/04. doi: 10.1099/mic.0.2008/018895-0 PMID: 18832305
31. Vandal OH, Nathan CF, Ehrt S. Acid resistance inMycobacterium tuberculosis. J Bacteriol. 2009; 191
(15):4714–21. Epub 2009/05/26. doi: 10.1128/JB.00305-09 PMID: 19465648
32. Welsh KJ, Hwang S-A, Boyd S, Kruzel ML, Hunter RL, Actor JK. Influence of oral lactoferrin onMyco-
bacterium tuberculosis induced immunopathology. Tuberculosis. 2011; 91(S1):S105–S13.
33. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic pro-
tein c defines newmechanismsmodulating inflammation and apoptosis. J Biol Chem. 2001; 276
(14):11199–203. Epub 2001/03/30. PMID: 11278252
34. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations and safety. Am J Clin Nutr.
1999; 69:842–56. PMID: 10232622
35. Sarker P, Ahmed S, Tiash S, Rekha RS, Stromberg R, Andersson J, et al. Phenylbutyrate Counteracts
Shigella Mediated Downregulation of Cathelicidin in Rabbit Lung and Intestinal Epithelia: A Potential Ther-
apeutic Strategy. PLoSOne. 2011; 6(6):e20637. doi: 10.1371/journal.pone.0020637 PMID: 21673991
36. Raqib R, Sarker P, Bergman P, Ara G, Lindh M, Sack DA, et al. Improved outcome in shigellosis associ-
ated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci U S A. 2006; 103
(24):9178–83. Epub 2006/06/03. PMID: 16740661
37. Vigne S, Palmer G, Martin P, Lamacchia C, Strebel D, Rodriguez E, et al. IL-36 signaling amplifies Th1
responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. Blood. 2012; 120
(17):3478–87. Epub 2012/09/13. doi: 10.1182/blood-2012-06-439026 PMID: 22968459
38. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor
of innate immunity. Nat Immunol. 2010; 11(11):1014–22. Epub 2010/10/12. doi: 10.1038/ni.1944
PMID: 20935647
39. Netea MG, Azam T, Ferwerda G, Girardin SE, Kim SH, Dinarello CA. Triggering receptor expressed on
myeloid cells-1 (TREM-1) amplifies the signals induced by the NACHT-LRR (NLR) pattern recognition
receptors. J Leukoc Biol. 2006; 80(6):1454–61. Epub 2006/08/31. PMID: 16940328
40. Dower K, Ellis DK, Saraf K, Jelinsky SA, Lin LL. Innate immune responses to TREM-1 activation: over-
lap, divergence, and positive and negative cross-talk with bacterial lipopolysaccharide. J Immunol.
2008; 180(5):3520–34. Epub 2008/02/23. PMID: 18292579
41. Gibot S, Massin F, Marcou M, Taylor V, Stidwill R, Wilson P, et al. TREM-1 promotes survival during
septic shock in mice. Eur J Immunol. 2007; 37(2):456–66. Epub 2007/01/19. PMID: 17230441
42. Kulkarni NN, Yi Z, Huehnken C, Agerberth B, Gudmundsson GH. Phenylbutyrate induces cathelicidin
expression via the vitamin D receptor: Linkage to inflammatory and growth factor cytokines pathways.
Mol Immunol. 2014; 63(2):530–9. Epub 2014/12/03.
43. Toltl LJ, Beaudin S, Liaw PC. Activated protein C up-regulates IL-10 and inhibits tissue factor in blood
monocytes. J Immunol. 2008; 181(3):2165–73. Epub 2008/07/22. PMID: 18641355
44. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, et al. Activated protein C attenu-
ates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood.
1996; 87(2):642–7. Epub 1996/01/15. PMID: 8555486
45. Lowe DM, Redford PS,Wilkinson RJ, O'Garra A, Martineau AR. Neutrophils in tuberculosis: friend or foe?
Trends Immunol. 2012; 33(1):14–25. Epub 2011/11/19. doi: 10.1016/j.it.2011.10.003 PMID: 22094048
46. Wang JY, Hsueh PR, Lee LN, Liaw YS, ShauWY, Yang PC, et al.Mycobacterium tuberculosis induc-
ing disseminated intravascular coagulation. Thromb Haemost. 2005; 93(4):729–34. Epub 2005/04/21.
PMID: 15841321
47. van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA. Inflammasome activation and IL-1beta and
IL-18 processing during infection. Trends Immunol. 2011; 32(3):110–6. Epub 2011/02/22. doi: 10.1016/
j.it.2011.01.003 PMID: 21333600
48. van der Does AM, Kenne E, Koppelaar E, Agerberth B, Lindbom L. Vitamin D3 and phenylbutyrate pro-
mote development of a human dendritic cell subset displaying enhanced antimicrobial properties. J
Leukoc Biol. 95(6):883–91. Epub 2014/02/20. doi: 10.1189/jlb.1013549 PMID: 24550524
49. Portevin D, Gagneux S, Comas I, Young D. Human macrophage responses to clinical isolates from the
Mycobacterium tuberculosis complex discriminate between ancient and modern lineages. PLoS
Pathog. 2011; 7(3):e1001307. Epub 2011/03/17. doi: 10.1371/journal.ppat.1001307 PMID: 21408618
Phenylbutyrate and Vitamin D: Dual Immunotherapy for Tuberculosis
PLOS Pathogens | DOI:10.1371/journal.ppat.1005007 July 2, 2015 23 / 23
